Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin added to carboplatin-paclitaxel for ovarian cancer
IRCT20120922010901N7Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of metformin in epithelial ovarian cancer (EOC) and ovarian cancer (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Serum level of cancer antigen 125, Computed tomography response assessment and 1 more. Started Jul 2020; status: completed.
02
Drugs
metformin
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on IRCT20120922010901N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120922010901N7.